Sociedad Argentina de Hematología

ISSN 2250-8309


Declaración de Conflictos de Interés

Cesión de Derechos de Autor

Se solicita enviar ambos formularios a:




Revista Argentina de Hematología


Volumen:    21    # Number : 2

Publication Date :    Mayo - Agosto    Year:    2017


Access to diagnostic and therapeutic tools for myelodysplastic syndromes in Argentina

Authors: Crisp R1#, Flores G2#, Enrico A3#, Iastrebner M4#, Santos I#, Rivas M, Narbaiz M, Cismondi V, Alfonso G, Belli C

Abstract: Myelodysplastic syndromes are a heterogeneous group of clonal hematological diseases which diagnosis requires a multidisciplinary scenario. In addition to clinical manifestations and bone marrow and peripheral blood features, karyotyping is mandatory for the diagnosis. The histopathological analysis of the bone marrow and the immunophenotyping by flow cytometry contribute to the diagnostic confirmation. The prognostic systems have been designed in order to apply therapeutic strategies adapted to risk. The aim of this work is to evaluate results of a survey designed to report on currently available diagnostic and therapeutic tools for hematologists in Argentina. The survey was fulfilled by 195 hematologists belonging to every Regional of the Argentine Society of Hematology, throughout the XXII Argentine Congress of Hematology. Results showed that complementary studies for the diagnosis are requested by physicians, despite differences either on the availability for diagnostic tests between Regionals or the type of attention. The most commonly used risk stratification systems are IPSS and IPSS-R. Main factors which are taken into consideration by the physician to decide the treatment differ between adult and pediatric hematologists. Support measures, erythropoietin and azacitidine are most frequently used for treatment of adults, whereas the indication for allogeneic stem cell transplantation is more common among pediatricians. Treatment discontinuation is mainly due to lack of response, with the exception of chelation therapy which also presents a similar proportion of adverse effects. Addressing the Argentinean reality will allow us to design collaborative strategies to achieve adequate access and equity to our patients.

Key words: Myelodysplastic syndromes, Health survey

Pages :

  Resumen             pdf  

Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485